Quotient Clinical, the Translational Pharmaceutics Company, will present two poster publications at the forthcoming 11th International ISSX Meeting 2016 in Busan, South Korea.
The poster publications describe recent advancements in the design of integrated clinical programs to generate pivotal pharmacokinetic and metabolism data addressing key development and regulatory requirements.
Details of the poster presentations are:
- A phase I, open-label, 2-part study to establish absolute bioavailability and the absorption, metabolism and excretion of evogliptin in healthy male subjects by a light-label, Poster No P181, Session 1, Monday June 13th, 12.15- 1.00pm
- Absorption, metabolism and excretion of [14C]-gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans, Poster No P182, Session 2, Wednesday June 15th, 12.15- 1.00pm
Iain Shaw, Director 14C Enabled Drug Development, Quotient Sciences will be located at exhibition booth #61. Should you wish to arrange a meeting, please email Iain.Shaw@quotientclinical.com